Novartis Secures European Backing for First New Teen Skin Therapy in a Decade

2026-11-14 biotech

Amsterdam, Saturday 14 November 2026
European regulators backed Novartis’s Cosentyx for adolescents with severe hidradenitis suppurativa, poised to become Europe’s first new targeted biologic treatment for this painful, scarring condition in nearly ten years.

Regulatory Momentum at the EMA Headquarters

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), operating from its headquarters in Amsterdam, formally recommended the approval of Cosentyx (secukinumab) on 12 November 2026 [2][3]. Marketed by Novartis Europharm Limited, the drug is designated for adolescents aged 12 years and older presenting with active moderate to severe hidradenitis suppurativa (HS) who have shown an inadequate response to conventional systemic therapies [1][3][5]. Novartis announced the positive recommendation on 13 November 2026 [3][5]. The regulatory opinion was adopted during the CHMP’s plenary session held between 9 and 12 November 2026, during which the committee evaluated a total of seven new medicines and backed label extensions across 11 therapies [2].

Bridging a Critical Pediatric Therapeutic Void

Hidradenitis suppurativa, alternatively known as acne inversa, is a chronic, progressive, and highly debilitating inflammatory condition affecting up to 1% of the global population, or roughly 1 in 100 individuals [3][6]. The condition triggers recurring, painful abscesses and nodules in sensitive anatomical regions such as the axillae, groin, and inner thighs, which can rupture, create open wounds, and lead to irreversible structural scarring [1][3][5]. Crucially, more than 50% of all cases manifest during puberty [1][4][6]. According to Dr John Ingram, Clinical Professor at Cardiff University School of Medicine in the United Kingdom, the onset of HS during adolescence occurs at a critical juncture when tissue damage can become permanent, compounding a long-standing deficit in therapeutic options for this demographic [3][4].

Scientific Foundation and Pharmacokinetic Bridging

If formally approved by the European Commission, Cosentyx will stand as the only interleukin-17A (IL-17A) inhibitor authorised for adolescent HS across the European Union, representing the first novel biologic mechanism introduced for this adolescent cohort in nearly a decade [1][4]. The mechanism operates by directly neutralising the IL-17A cytokine, an inflammatory driver across multiple systemic conditions [1][3]. Cosentyx is already sanctioned in Europe for paediatric plaque psoriasis and juvenile idiopathic arthritis subtypes, including enthesitis-related arthritis and juvenile psoriatic arthritis from age six, and carries an existing paediatric HS indication in the United States [1][3][5].

Extrapolation Models and Clinical Evidence

The CHMP’s positive verdict was largely underpinned by pediatric pharmacokinetic modeling and weight-based dosing extrapolation rather than a dedicated teenage Phase III trial [1][5]. Exposure analyses confirmed that weight-adjusted regimens in adolescents aged 12 and older achieved drug concentrations comparable to adult patients [1][4]. Supporting adult efficacy stems from the identical Phase III SUNSHINE and SUNRISE trials, which evaluated 1,084 adult patients with moderate to severe disease [3][5]. Adult participants receiving secukinumab every two weeks demonstrated 16-week HiSCR50 response rates of 45.0% versus 33.7% for placebo in SUNSHINE—an absolute difference of 11.3 percentage points—and 42.3% versus 31.2% in SUNRISE, representing an absolute advantage of 11.1 percentage points [3][5].

Timeline Towards Commercial Rollout

The positive CHMP recommendation now transitions to the European Commission, which typically issues legally binding marketing authorisation decisions within approximately two months of an opinion, placing the final verdict around mid-January 2027 [1][3][4]. Novartis International President Patrick Horber, M.D., and university researchers have highlighted that closing this adolescent treatment gap via earlier biologic intervention could substantially alleviate lifetime scarring and structural tissue morbidity [6]. The pending decision represents a notable commercial lifecycle extension for the Swiss pharmaceutical giant as it consolidates its anti-inflammatory footprint across Europe [1][4].

Sources & Ecosystem Partners

Biologics approval Regulatory affairs